GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14 août 2024 16h05 HE
|
GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H...
Digital Brands Group to Report Second Quarter 2024 Financial Results on Monday, August 19, 2024
14 août 2024 10h00 HE
|
Digital Brands Group, Inc.
Austin, TX, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Digital Brands Group, Inc. (“DBG”) (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands, will report financial results for the...
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14 août 2024 08h05 HE
|
GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
Vislink Reports Second Quarter 2024 Financial and Operational Results
14 août 2024 08h00 HE
|
Vislink Technologies, Inc.
Q2 Revenue Jumps 73% Year-Over-Year to $8.7 Million, First Six Months Revenue Reaches $17.3 Million Vislink Lands Government Orders and Expands Market Reach with Assignment of NATO Stock Numbers...
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
14 août 2024 08h00 HE
|
Cocrystal Pharma, Inc.
Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial indication of virologyIn vitro testing shows CC-42344 inhibits the avian...
Polar Power Reports Second Quarter 2024 Financial Results
14 août 2024 08h00 HE
|
Polar Power, Inc.
Swing to Quarterly Profit Led by Higher Net Sales GARDENA, CA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime,...
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
13 août 2024 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
13 août 2024 08h05 HE
|
Palisade Bio, Inc.
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Company continues to...
CareCloud Reports Second Quarter 2024 Results
13 août 2024 07h00 HE
|
CareCloud, Inc
Continued Focus on Profitability and Free Cash Flow SOMERSET, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and...
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
09 août 2024 16h15 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...